These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38752732)

  • 21. A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients.
    Leonart LP; Tonin FS; Ferreira VL; Penteado STS; Wiens A; Motta FA; Pontarolo R
    J Clin Pharm Ther; 2017 Oct; 42(5):530-538. PubMed ID: 28620958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
    Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
    Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
    Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of fungal disease in the setting of neutropenia.
    Walsh TJ; Gamaletsou MN
    Hematology Am Soc Hematol Educ Program; 2013; 2013():423-7. PubMed ID: 24319214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients.
    Ju C; Lian Q; Chen A; Zhao B; Zhou S; Cai Y; Xie H; Wei L; Li S; He J
    Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36036471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimold Prophylaxis May Reduce the Risk of Invasive Fusariosis in Hematologic Patients with Superficial Skin Lesions with Positive Culture for Fusarium.
    Varon AG; Nouér SA; Barreiros G; Trope BM; Akiti T; Nucci M
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7290-7294. PubMed ID: 27671065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
    Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
    Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?
    Jenks JD; Mehta SR; Hoenigl M
    Med Mycol; 2019 Apr; 57(Supplement_2):S168-S178. PubMed ID: 30816967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in the epidemiological landscape of invasive mould infections and disease.
    Lass-Flörl C; Cuenca-Estrella M
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
    Clark NM; Grim SA; Lynch JP
    Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
    Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
    Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of drug-resistant Aspergillus infection.
    Aigner M; Lass-Flörl C
    Expert Opin Pharmacother; 2015; 16(15):2267-70. PubMed ID: 26328502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.
    Van Matre ET; Evans SL; Mueller SW; MacLaren R; Fish DN; Kiser TH
    Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):13. PubMed ID: 30894179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
    Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
    Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies.
    Perreault S; McManus D; Anderson A; Lin T; Ruggero M; Topal JE
    J Oncol Pharm Pract; 2019 Sep; 25(6):1305-1311. PubMed ID: 29996736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world Use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results From a Subgroup Analysis of a Multicenter National Registry.
    Nguyen MH; Ostrosky-Zeichner L; Pappas PG; Walsh TJ; Bubalo J; Alexander BD; Miceli MH; Jiang J; Song Y; Thompson GR
    Open Forum Infect Dis; 2023 Sep; 10(9):ofad424. PubMed ID: 37674634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients.
    Khatri AM; Natori Y; Anderson A; Jabr R; Shah SA; Natori A; Chandhok NS; Komanduri K; Morris MI; Camargo JF; Raja M
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14162. PubMed ID: 37794708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
    Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New antifungal agents.
    Gupta AK; Tomas E
    Dermatol Clin; 2003 Jul; 21(3):565-76. PubMed ID: 12956208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.